A Phase I/II, Open Label, Multi-Center Study For The Evaluation Of CPG 7909 [Agatolimod] In Patients With Stage Iv Renal Cell Carcinoma

Trial Profile

A Phase I/II, Open Label, Multi-Center Study For The Evaluation Of CPG 7909 [Agatolimod] In Patients With Stage Iv Renal Cell Carcinoma

Completed
Phase of Trial: Phase I/II

Latest Information Update: 13 Jan 2009

At a glance

  • Drugs Agatolimod (Primary)
  • Indications Renal cell carcinoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 13 Jan 2009 Official title updated from ClinicalTrials.gov record. Actual end date reported as September 2004; actual patient number is 42.
    • 20 Jun 2007 Pfizer has discontinued the PF-3512676 development programme because of no evidence of additional clinical efficacy compared with standard antineoplastics alone.
    • 07 Aug 2006 Status change
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top